Immediate treatment probably leads to higher adverse events (control ‐ deferred treatment) compared with controls (moderate certainty).
Immediate treatment may leads to higher adverse events (control ‐ no treatment) compared with controls (low certainty).
Untargeted antifungal treatment with any antifungal drug (systemic… showed no clear difference in adverse events requiring cessation of study drug(s) compared with placebo/no antifungal/any other antifungal (low certainty).
It is very uncertain whether DOPAMINERGIC DRUGS changes acceptability of treatment: Leaving the study early compared with OTHER DRUGS (very low certainty).
Antibiotic treatment showed no clear difference in microbial resistance to prophylactic drug compared with placebo or no treatment (moderate certainty).
The review found no eligible studies for this question.
Antifungal drugs absorbed from GI tract showed no clear difference in empirical antifungal treatment compared with antifungal drugs not absorbed from GI tract; GRADE not reported.
Antifungal drugs absorbed from GI tract showed no clear difference in toxicity (adverse events probably due to drug) compared with antifungal drugs not absorbed from GI tract; GRADE not reported.
Antifungal drugs partially absorbed from GI tract (miconazole,… showed no clear difference in empirical antifungal treatment compared with placebo or no treatment; GRADE not reported.
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… led to lower empirical antifungal treatment compared with placebo or no treatment; GRADE not reported.
Antifungal drugs absorbed from GI tract (fluconazole, ketoconazole,… showed no clear difference in toxicity (adverse events probably due to drug) compared with placebo or no treatment; GRADE not reported.
SCS treatment for 7 or fewer days showed no clear difference in adverse drug effect—hyperglycaemia compared with SCS treatment (moderate certainty).
SCS treatment for 7 or fewer days showed no clear difference in adverse drug effects Gastrointestinal tract bleeding, symptomatic… compared with SCS treatment (low certainty).
Olanzapine showed no clear difference in participant preference ‐ wish to use drug in next treatment compared with placebo/no treatment (moderate certainty).
It is very uncertain whether are disease‐modifying drugs for a first attack suggestive of… changes disability‐worsening Proportion of participants with… compared with placebo? (very low certainty).
It is very uncertain whether are disease‐modifying drugs for a first attack suggestive of… changes relapse Proportion of participants with relapse during 24 months of… compared with placebo? (very low certainty).